Aydogdu I, Koc H, Ilhan O, Gurman G, Akan H, Beksac M, Konuk N, Uysal A, Ozerol E
Department of Hematology, School of Medicine, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey.
Haematologia (Budap). 1997;28(4):207-13.
In recent years, more effective and less toxic treatment protocols have been developed to increase the cure rates in intermediate and high grade non-Hodgkin's lymphoma (NHL). This study was undertaken to investigate the efficacy and toxicity of MINE (ifosfamide, mesna, mitoxantrone and etoposide) combination chemotherapy in patients with intermediate and high grade NHL. Twenty-one patients (16 male, 5 female; age between 26 and 70 years) with NHL were included in the study. An overall response rate of 73% and complete response rate of 56% were achieved and survival rate for responding patients was 80% at the 48th month. Side effects including mild myelosuppression, nausea/vomiting and alopecia were observed. MINE combination seems to be effective and well tolerated without significant toxicity as a first-line therapy in patients with intermediate or high grade NHL.
近年来，已开发出更有效且毒性更低的治疗方案，以提高中、高级别非霍奇金淋巴瘤（NHL）的治愈率。本研究旨在调查MINE（异环磷酰胺、美司钠、米托蒽醌和依托泊苷）联合化疗对中、高级别NHL患者的疗效和毒性。21例（16例男性，5例女性；年龄在26至70岁之间）NHL患者纳入本研究。总缓解率为73%，完全缓解率为56%，缓解患者在第48个月的生存率为80%。观察到包括轻度骨髓抑制、恶心/呕吐和脱发在内的副作用。MINE联合化疗作为中、高级别NHL患者的一线治疗方案似乎有效且耐受性良好，无明显毒性。
